Biopharma Excellence

What Biopharma Excellence does

Biopharma Excellence is a privately held, for-profit biopharma consulting firm headquartered in München (Munich), Germany. Founded in 2013, the firm operates with a small team of 1–10 employees and provides specialised consulting services focused on biologicals, antibody-containing products, and vaccines. Its public web presence is biopharma-excellence.com, and the firm is classified as private with no IPO status disclosed.

The firm's business model is consulting-led: it monetises domain expertise across complex biologics modalities, including antibodies and vaccine products, for clients in the biopharmaceutical industry. There is no disclosed pricing model, customer roster, named leadership, partnership network, or revenue figure in the aggregated input, and the firm has no documented funding rounds, M&A activity, regulatory actions, or restructuring events on record. The api_details, integrations, products_and_services, investments, contact_details, management_team, mergers_and_acquisitions, corporate_structural_moves, and restructuring_and_leadership_changes fields are all empty in the source data, which materially limits observable signal about commercial traction or strategic direction.

Note on source composition: the aggregated input contains a large volume of material describing Cencora, Inc. (NYSE: COR), a U.S.-listed pharmaceutical solutions company specialising in cell and gene therapy distribution and commercialisation. That material pertains to a separate legal entity headquartered in the United States with thousands of employees and billions in revenue, and is not used to characterise Biopharma Excellence in this analysis. All inferences above are drawn strictly from Biopharma Excellence–labelled firmographic data.

Name

Biopharma Excellence

Legal name

Cencora, Inc.

Website

https://biopharma-excellence.com

Company type

Public

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Consulting Services

NAICS

Other Scientific and Technical Consulting Services (54169), Management, Scientific, and Technical Consulting Services (5416)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAKAL

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

SECONDARYHLAGAGAL

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

SECONDARYHLAGAKAO

Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

• Biopharma consulting
• Vaccine consulting
• Biologicals consulting
• Antibody product consulting
• Biopharmaceutical advisory

Headquarters

HQ city

München

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Regulatory Affairs and CMC Services: Guidance informed by regular engagements with global agencies, chemistry manufacturing controls (CMC) services, and assistance with special designations and programs for advanced therapies.
2. Market Access Strategy: Differentiating and delivering brand value proposition worldwide with timely advice on market access strategy and execution throughout the product life cycle.
3. Pharmacovigilance Services: Patient safety services supporting manufacturers in recording safety and efficacy of therapies from clinical development through post-market surveillance, experienced in U.S., European, and Canadian regulations.
4. Third-Party Logistics (3PL): Innovative logistics solutions tailored to advanced therapies including transport, warehousing, inventory management, and distribution for clinical and commercial operations.
5. Specialty Distribution: Channel strategy design, order-to-cash management, and global distribution with temperature-controlled solutions ensuring optimal market and patient access.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Biopharma Excellence provides specialised biopharma consulting services covering biologicals, antibody-containing products, and vaccines. The firm delivers expert advisory support to biopharmaceutical developers operating in these product categories. As a small privately held firm (1–10 employees), it operates as a boutique consultancy based in München, Germany.

Product overview

Cencora offers an integrated suite of cell and gene therapy services spanning the entire product lifecycle from early discovery through commercialization. The portfolio includes Regulatory Affairs and CMC Services, Market Access Strategy, Pharmacovigilance, Third-Party Logistics (3PL), Specialty Distribution Networks, and Specialty Logistics. These services are connected through the Cencora Orchestration Exchange platform, which provides integrated visibility across the treatment journey. The company supports over 230 active cell and gene biopharma partners and has experience with 30+ FDA/EMA-approved therapies, offering comprehensive support including temperature-controlled distribution and 30,000+ annual LN2 and cryogenic shipments.

Differentiator

Problem solved

Functional benefit

Brands

• Cencora Ventures: Corporate venture fund supporting the growth of leading-edge entrepreneurial businesses.

Products and services

• Biologicals Consulting
• Antibody-Containing Product Consulting
• Vaccine Consulting

Quantifiable outcome

• 30,000+ global LN2 and cryogenic shipments annually
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators6 records

Expansion highlights1 record

Direct peers

• PharmaLex (Cencora): Specialised biopharma regulatory, quality, and pharmacovigilance consulting firm (acquired by Cencora in 2023). Direct competitor for EU QP services, GMP quality, and biologics/vaccine regulatory work.
• Voisin Consulting Life Sciences (VCLS): Independent regulatory and HTA consultancy with strong biologics and advanced therapy practice, headquartered in Europe. Directly comparable in scope of regulatory affairs, CMC and quality services for biologics and vaccines.
• Regenold GmbH: German specialist consultancy providing regulatory affairs and CMC services to biopharma, including biologics. Closely comparable German SME competitor with similar service scope and customer base.
• ProPharma Group: Global regulatory, quality, and compliance consulting firm serving pharmaceutical and biotechnology clients, with explicit biologics and vaccine expertise. Closely comparable mid-sized consulting model.
• Biopharma Group: UK-based specialist consultancy offering regulatory, quality, and analytical services to biopharmaceutical manufacturers, including vaccines and antibody therapeutics. Comparable in modality focus and consulting-only model.

Broad incumbents

• ICON plc: Global CRO offering regulatory affairs, biopharma development, and laboratory services across biologics and vaccines. Competes for the same EU biopharma regulatory and quality mandates but as a much larger, broad-line provider.
• IQVIA: Large life-sciences services company providing regulatory, quality, and commercialisation consulting alongside its core CRO franchise. Overlaps with Biopharma Excellence's EU regulatory and quality offering at the larger end of the market.
• Charles River Laboratories: Global CRO/CDMO offering biologics testing, manufacturing, and regulatory consulting services. Competes in the same biologics/vaccine regulatory and quality services category from a much broader portfolio base.
• Parexel International: Global CRO with significant biopharma regulatory and biopharmaceutical development services, including work on vaccines and biologics. Larger-scale competitor for the same kind of sponsor mandates.

Regional players

• PharmaAdvisors / Biopharma Excellence peers: Boutique regulatory affairs and GxP quality consultancy serving EU biopharma clients on biologics, vaccines, and advanced therapies. Comparable in size, service scope, and customer profile, with strong overlap to a Munich-based German SME.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xtwitter.com/CencoraGlobal
• Facebookfacebook.com/Cencora
• LinkedInlinkedin.com/company/cencoraglobal
• Instagraminstagram.com/cencoraglobal

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopharma Excellence